Ownership Submission
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
Went Gregory T
   2. Issuer Name and Ticker or Trading Symbol
Adamas Pharmaceuticals Inc [ADMS] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director __X__ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Chief Executive Officer
(Last)
(First)
(Middle)
C/O ADAMAS PHARMACEUTICALS, INC., 1900 POWELL ST., SUITE 750		 3. Date of Earliest Transaction (Month/Day/Year)
04/10/2015
(Street)

EMERYVILLE, CA 94608		 4. If Amendment, Date Original Filed(Month/Day/Year)
 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)		 7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 04/10/2015   M   1,000 A $ 1.875 11,008 (1) D  
Common Stock 04/10/2015   S   900 D $ 18.0889 (2) 10,108 (1) D  
Common Stock 04/10/2015   S   100 D $ 19 10,008 (1) D  
Common Stock 04/10/2015   S   3,077 D $ 18.1595 (3) 402,903 (1) I Gregory T Went & Marjorie S Went ttees Went Family Living Trust dtd 03/24/11
Common Stock 04/10/2015   S   500 D $ 19.07 (4) 402,403 (1) I Gregory T Went & Marjorie S Went ttees Went Family Living Trust dtd 03/24/11
Common Stock 04/14/2015   M   80 A $ 1.875 10,088 (1) D  
Common Stock 04/14/2015   S   80 D $ 18 10,008 (1) D  
Common Stock 04/14/2015   S   10,000 A $ 1.875 20,008 (1) D  
Common Stock 04/14/2015   S   100 D $ 18 402,303 (1) I Gregory T Went & Marjorie S Went ttees Went Family Living Trust dtd 03/24/11
Common Stock               6,666 I Gregory T Went Cust - Bridget Went Under CA Uniform Transfers to Minors Act
Common Stock               6,666 I Gregory T Went Cust - Cora Went Under CA Uniform Transfers to Minors Act
Common Stock               80,000 I Gregory T Went & Marjorie S Went ttees 2012 Irr Trust FBO Bridget Elise Went
Common Stock               80,000 I Gregory T Went & Marjorie S Went ttees 2012 Irr Trust FBO Cora Margaret Went

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)		 6. Date Exercisable and Expiration Date
(Month/Day/Year)		 7. Title and Amount of Underlying Securities
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)		 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)		 11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $ 1.875 04/10/2015   M     1,000   (5) 09/12/2016 Common Stock 1,000 $ 0 230,080 D  
Stock Option (Right to Buy) $ 1.875 04/14/2015   M     80   (5) 09/12/2016 Common Stock 80 $ 0 230,000 D  
Stock Option (Right to Buy) $ 1.875 04/14/2015   M     10,000   (5) 09/12/2016 Common Stock 10,000 $ 0 220,000 D  

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
Went Gregory T
C/O ADAMAS PHARMACEUTICALS, INC.
1900 POWELL ST., SUITE 750
EMERYVILLE, CA 94608		   X   X   Chief Executive Officer  

Signatures

 /s/Grace Shin, as Attorney-in-Fact   04/14/2015
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
(2) This transaction was executed in multiple trades at prices ranging from $18.00 to $18.31. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
(3) This transaction was executed in multiple trades at prices ranging from $18.00 to $18.99. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
(4) This transaction was executed in multiple trades at prices ranging from $19.00 to $19.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
(5) This option is fully vested and exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.